Clinical and Cost Effectiveness of Mobile Phone Supported Self Monitoring of Asthma: Multicentre Randomised Controlled Trial
Overview
Authors
Affiliations
Objective: To determine whether mobile phone based monitoring improves asthma control compared with standard paper based monitoring strategies.
Design: Multicentre randomised controlled trial with cost effectiveness analysis.
Setting: UK primary care.
Participants: 288 adolescents and adults with poorly controlled asthma (asthma control questionnaire (ACQ) score ≥ 1.5) from 32 practices.
Intervention: Participants were centrally randomised to twice daily recording and mobile phone based transmission of symptoms, drug use, and peak flow with immediate feedback prompting action according to an agreed plan or paper based monitoring.
Main Outcome Measures: Changes in scores on asthma control questionnaire and self efficacy (knowledge, attitude, and self efficacy asthma questionnaire (KASE-AQ)) at six months after randomisation. Assessment of outcomes was blinded. Analysis was on an intention to treat basis.
Results: There was no significant difference in the change in asthma control or self efficacy between the two groups (ACQ: mean change 0.75 in mobile group v 0.73 in paper group, mean difference in change -0.02 (95% confidence interval -0.23 to 0.19); KASE-AQ score: mean change -4.4 v -2.4, mean difference 2.0 (-0.3 to 4.2)). The numbers of patients who had acute exacerbations, steroid courses, and unscheduled consultations were similar in both groups, with similar healthcare costs. Overall, the mobile phone service was more expensive because of the expenses of telemonitoring.
Conclusions: Mobile technology does not improve asthma control or increase self efficacy compared with paper based monitoring when both groups received clinical care to guidelines standards. The mobile technology was not cost effective.
Trial Registration: Clinical Trials NCT00512837.
EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR.
Scadding G, Conti D, Scheire S, Backer V, Blaiss M, Cardell L Front Allergy. 2025; 5:1531788.
PMID: 39963330 PMC: 11830706. DOI: 10.3389/falgy.2024.1531788.
Poot C, de Boer J, Goto L, van de Hei S, Chavannes N, Visch V Patient Prefer Adherence. 2023; 17:2719-2736.
PMID: 37933305 PMC: 10625736. DOI: 10.2147/PPA.S423161.
Digital Action Plan (Web App) for Managing Asthma Exacerbations: Randomized Controlled Trial.
Beydon N, Taille C, Corvol H, Valcke J, Portal J, Plantier L J Med Internet Res. 2023; 25:e41490.
PMID: 37255277 PMC: 10365576. DOI: 10.2196/41490.
Expectations and Prior Experiences Associated With Adverse Effects of COVID-19 Vaccination.
Schafer I, Oltrogge J, Nestoriuc Y, Warren C, Brassen S, Blattner M JAMA Netw Open. 2023; 6(3):e234732.
PMID: 36972051 PMC: 10043751. DOI: 10.1001/jamanetworkopen.2023.4732.
van de Hei S, Poot C, van den Berg L, Meijer E, van Boven J, Flokstra-de Blok B BMJ Open Respir Res. 2022; 9(1).
PMID: 36522130 PMC: 9756226. DOI: 10.1136/bmjresp-2022-001400.